Safety and Tolerability of Lanreotide Autogel/Depot (LAN) in Patients (pts) with Neuroendocrine Tumours (NETs): Pooled Analysis of Clinical Studies

被引：0
|
作者：
Phan, A. T. [1 ]
Wolin, E. M. [2 ]
Fisher, G. A. [3 ]
Ruszniewski, P. [4 ]
Pavel, M. [5 ]
Liyanage, N. [6 ]
Mirakhur, B. [7 ]
Braun, S. [6 ]
Caplin, M. [8 ]
Vinik, A., I [9 ]
机构：
[1] Univ New Mexico, Ctr Canc, Albuquerque, NM 87131 USA
[2] Montefiore Einstein Ctr Canc Care, Bronx, NY USA
[3] Stanford Univ, Stanford, CA 94305 USA
[4] Beaujon Hosp, Clichy, France
[5] Charite Univ Med Berlin, Berlin, Germany
[6] Ipsen, Les Ulis, France
[7] Ipsen, Basking Ridge, NJ USA
[8] Royal Free Hosp, London, England
[9] Eastern Virginia Med Sch, Norfolk, VA 23501 USA
来源：
NEUROENDOCRINOLOGY | 2017年 / 105卷
关键词：
lanreotide; safety;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
K17
引用
收藏
页码：206 / 206
页数：1
相关论文
共 50 条
  • [31] Lanreotide depot/autogel (LAN) in patients with neuroendocrine tumors (NETs) aged ≤65 vs. >65 years: Subgroup analyses from the CLARINET study.
    Dasari, A.
    Phan, Alexandria T.
    Caplin, Martyn E.
    Pavel, Marianne E.
    Cwikla, Jaroslaw B.
    Raderer, Markus
    Sedlackova, Eva
    Cadiot, Guillaume
    Wolin, Edward M.
    Capdevila, Jaume
    Wall, Lucy
    Rindi, Guido
    Langley, Alison
    Gomez-Panzani, Edda
    Ruszniewski, Philippe B.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [32] Co-Creation of a Lanreotide Autogel/Depot Syringe for the Treatment of Acromegaly and Neuroendocrine Tumours Through Collaborative Human Factor Studies
    Adelman, Daphne T.
    Van Genechten, Dirk
    Megret, Clementine M.
    Thanh, Xuan-Mai T. Truong
    Hand, Philippa
    Martin, Wendy A.
    ADVANCES IN THERAPY, 2019, 36 (12) : 3409 - 3423
  • [33] Co-Creation of a Lanreotide Autogel/Depot Syringe for the Treatment of Acromegaly and Neuroendocrine Tumours Through Collaborative Human Factor Studies
    Daphne T. Adelman
    Dirk Van Genechten
    Clémentine M. Megret
    Xuan-Mai T. Truong Thanh
    Philippa Hand
    Wendy A. Martin
    Advances in Therapy, 2019, 36 : 3409 - 3423
  • [34] Prognostic factors for progression-free survival (PFS) in CLARINET study of lanreotide depot/autogel (LAN) vs placebo (PBO) in neuroendocrine tumors (NETs).
    Wolin, Edward M.
    Caplin, Martyn E.
    Pavel, Marianne E.
    Cwikla, Jaroslaw B.
    Phan, Alexandria T.
    Raderer, Markus
    Sedlackova, Eva
    Cadiot, Guillaume
    Capdevila, Jaume
    Wall, Lucy
    Rindi, Guido
    Langley, Alison
    Gomez-Panzani, Edda
    Ruszniewski, Philippe B.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [35] Lanreotide depot/autogel (LAN) in intestinal and pancreatic neuroendocrine tumors (NETs) according to body mass index (BMI): Subgroup analyses from the CLARINET study.
    Wolin, Edward M.
    Caplin, Martyn E.
    Pavel, Marianne E.
    Cwikla, Jaroslaw B.
    Phan, Alexandria T.
    Raderer, Markus
    Sedlackova, Eva
    Cadiot, Guillaume
    Capdevila, Jaume
    Wall, Lucy
    Rindi, Guido
    Langley, Alison
    Gomez-Panzani, Edda
    Ruszniewski, Philippe B.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [36] Safety and efficacy of lanreotide depot/autogel (LAN) in patients with lung NETs: The randomized, double-blind, placebo (PBO)-controlled phase III SPINET study.
    Reidy, Diane Lauren
    Kulke, Matthew H.
    Wolin, Edward M.
    Singh, Simron
    Ferone, Diego
    Mirakhur, Beloo
    Massien, Christine
    Houchard, Aude
    Caplin, Martyn E.
    Baudin, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [37] Correction to: Co-Creation of a Lanreotide Autogel/Depot Syringe for the Treatment of Acromegaly and Neuroendocrine Tumours Through Collaborative Human Factor Studies
    Daphne T. Adelman
    Dirk Van Genechten
    Clémentine M. Megret
    Xuan-Mai T. Truong Thanh
    Philippa Hand
    Wendy A. Martin
    Advances in Therapy, 2020, 37 : 975 - 976
  • [38] Long-Term Efficacy and Safety with Lanreotide Autogel/ Depot (LAN) from CLARINET and Open-Label Extension (OLE) Studies
    Phan, A. T.
    Pavel, M.
    Caplin, M.
    Wolin, E. M.
    Mirakhur, B.
    Massien, C.
    Liyanage, N.
    Lowenthal, Pittman S.
    Ruszniewski, P.
    NEUROENDOCRINOLOGY, 2017, 105 : 207 - 207
  • [39] Tumor Response in the CLARINET Study of Lanreotide Depot/Autogel vs Placebo in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2016, 14 (03) : 11 - 12
  • [40] Effects of lanreotide autogel/depot (LAN) in patients with neuroendocrine tumors (NETs) age 65 or younger versus older than age 65: Subgroup analyses from the CLARINET study.
    Phan, Alexandria T.
    Caplin, Martyn E.
    Pavel, Marianne E.
    Cwikla, Jaroslaw B.
    Raderer, Markus
    Sedlackova, Eva
    Cadiot, Guillaume
    Wolin, Edward M.
    Capdevila, Jaume
    Wall, Lucy
    Rindi, Guido
    Langley, Alison
    Gomez-Panzani, Edda
    Ruszniewski, Philippe B.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
12345